A phase I/II multicentric study to determine the safety and efficacy of a combination of Anti-CD3 & Anti-CD7 ricin A immunotoxins for the treatment of steroid-resistant acute graft-versus-host disease

Trial Profile

A phase I/II multicentric study to determine the safety and efficacy of a combination of Anti-CD3 & Anti-CD7 ricin A immunotoxins for the treatment of steroid-resistant acute graft-versus-host disease

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 01 May 2009

At a glance

  • Drugs Anti-CD3-ricin chain A conjugate/anti-CD7-ricin chain A conjugate (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2009 Planned initiation date changed from 1 Nov 2008 to 1 Jan 2010 as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned end date changed from 1 Nov 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Planned initiation date changed from 1 Sep 2008 to 1 Nov 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top